<DOC>
	<DOCNO>NCT02638168</DOCNO>
	<brief_summary>Over 10 % child United States diagnose ADHD , nearly half child moderate severe impairment sleep , exacerbate already impaired academic , emotional social functioning . In child ADHD , 34 % prescribed sleep medication antipsychotic cause mark weight gain metabolic change ; alternate medication either find ineffective , difficult tolerate largely unstudied youth . Delayed sleep onset strongly correlate active symptom ADHD Oppositional Defiant Disorder ( ODD ) , suggest good control disruptive behavior could improve sleep pattern application ass extension therapeutic effect CNS stimulant early even improves sleep onset .</brief_summary>
	<brief_title>Effects Evening Dose Immediate Release Methylphenidate Sleep Children With ADHD</brief_title>
	<detailed_description>The goal application assess impact safer treatment option Methylphenidate ( MPH ) sleep behavior problem child Attention Deficit Hyperactivity Disorder ( ADHD ) Behavioral Insomnia Childhood ( BIC ) . ADHD affect 11 % school-aged youth . Similarly , pediatric sleep disorder occur third child impact multiple domains child 's functioning well parent . Children ADHD increase risk sleep problem stagger comorbidity 70 % , sleep deprivation worsens already impaired social , emotional academic functioning child ADHD . Therefore , improve sleep may translate enhance function multiple realm . Delayed sleep onset latency ( SOL ) bedtime resistance , key component limit set type BIC , particularly likely occur child ADHD . Medications commonly use condition 6 % school-aged child United States prescribe medication ADHD 7 % sleep . In child ADHD , 34 % prescribed sleep medication antipsychotic cause mark weight gain metabolic change . Alternate medication sleep either find ineffective , difficult tolerate largely unstudied youth . MPH extensive database support safety efficacy . Objective sleep study MPH find consistent result , study report delay SOL others report improve quality sleep . Therefore , proposal evaluate impact extend MPH treatment early even sleep onset use 3-week with-in subject randomize trial .3mg/kg immediate release ( IR ) MPH dose 3 hour bedtime vs. placebo 38 child ADHD chronically delay SOL history prolong stimulant usage . The investigator recruit 38 child age 6-12 gender racial/ethnic status ADHD treat stable morning dose extend release ( ER ) MPH extend time period ( 30 day ) primary care psychiatry clinic Hershey Medical Center Hershey , PA . Recruitment split three wave ( 13 , 13 , 12 participant ) . Parents remind administer blind medication dose text message evening ( phone call study staff ) 3 hour prior desire bedtime . Sleep onset measure actigraphy sleep log , parent also report level ODD ADHD symptom even .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>1 . Ages 612 ( inclusive ) , able swallow capsule 2 . Children treat stable morning dose Extended Release Methylphenidate twice daily dose Immediate Release Methylphenidate extend period time ( 30 day longer ) . 3 . DSM V diagnosis Attention Deficit Hyperactivity Disorder ( ADHD ) : Diagnosis assess NIMH Computerized Diagnostic Interview Schedule Children ( CDISC ) , parent teacher rating scale . 4 . Children ADHD subtype meeting criterion eligible , although , expect majority combine subtype ADHD give associate subtype ODD symptom . A diagnosis two Behavioral Insomnia Childhood ( BIC ) subtypes associate delayed SOL ( limit set combine type ) require . 5 . Sex : male female 6 . Fluent write spoken English . 1 . Age &lt; 6 year age &gt; 12 year age . 2 . Children Methylphenidate ( Extended Release ) treatment extended period time ( 30 day longer ) . 3 . A diagnosis suspicion sleepdisordered breathe exclusionary expect impacted Immediate Release Methylphenidate treatment . 4 . Current psychotropics Methylphenidate ( Extended Release Immediate Release Methylphenidate ) . Children prescribe alpha agonist adjunctive control ADHD combination MPH product allow enroll long meet entry criterion ( i.e . sleep must remain impaired use alpha agonist ) . 5 . Regular use medication impact sleep within last 14 day ( i.e . : sedating antihistamine , melatonin ) . 6 . Active medical/psychiatric condition impact sleep ( i.e . : severe asthma , Autism Spectrum Disorder diagnosis , mark developmental delay , mood/anxiety disorder ) .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>